DOI: 10.1002/ame2.12339
Development of radiation countermeasure agents for acute radiation syndromes
Bowen Guan1
Deguan Li2
Aimin Meng1
1.National Human Diseases Animal Model Resource Center,NHC Key Laboratory of Human Disease Comparative Medicine,Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases,Institute of Laboratory Animal Sciences Chinese Academy of Medical Sciences(CAMS),Peking Union Medical College(PUMC),National Center of Technology Innovation for Animal Model,Beijing,China2.Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine,Institute of Radiation Medicine,Chinese Academy of Medical Science,Peking Union Medical College,Tianjin,China
摘要：The risk of internal and external exposure to ionizing radiation(IR)has increased alongside the development and implementation of nuclear technology.Therefore,serious security issues have emerged globally,and there has been an increase in the number of studies focusing on radiological prevention and medical countermeasures.Radioprotective drugs are particularly important components of emergency medical preparedness strategies for the clinical management of IR-induced injuries.However,a few drugs have been approved to date to treat such injuries,and the related mecha-nisms are not entirely understood.Thus,the aim of the present review was to provide a brief overview of the World Health Organization's updated list of essential medi-cines for 2023 for the proper management of national stockpiles and the treatment of radiological emergencies.This review also discusses the types of radiation-induced health injuries and the related mechanisms,as well as the development of various radioprotective agents,including Chinese herbal medicines,for which significant sur-vival benefits have been demonstrated in animal models of acute radiation syndrome.
机标关键词：developmentagentsacutecountermeasureradiationsyndromes
论文发表日期：2023-08-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：8( 329-336 )
英文信息